A statement released earlier today by RBC Capital Markets about Merus Labs International (NDAQ:MRUS) raises the target price to $28.00

Yesterday Merus Labs International (NDAQ:MRUS) traded -0.81% lower at $15.92. The company’s 50-day moving average is $15.72 and its 200-day moving average is $21.83. The last closing price is down -29.68% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time period. 4,054 shares of the stock traded hands, down from an average trading volume of 6,625

Merus Labs International (NDAQ:MRUS) had its price target upped to $28.00 by RBC Capital Markets in an issued report issued 9/15/2017. The upped price target implies a potential upside of 0.76% from the company’s most recent stock price close.

Previously on 5/5/2017, Jefferies & Co reported on Merus Labs International (NDAQ:MRUS) reduced the target price from $33.00 to $31.00. At the time, this indicated a possible upside of 0.57%.

See Chart Below

Merus Labs International has a 52 week low of $10.15 and a 52 week high of $29.75 The company’s market cap is currently $0.

In addition to RBC Capital Markets reporting its stock price target, a total of 4 brokers have issued a research note on the company. The average stock price target is $16.28 with zero analysts rating the company a strong buy, zero firms rating the stock a buy, 0 firms rating the stock a hold, zero equity analysts rating the company a underperform, and lastly zero brokers rating the stock a sell.

General Information About Merus Labs International (NDAQ:MRUS)

Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products inlcude, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as wellas MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *


14 − 6 =